Sanofi reported stronger than expected third-quarter profit on Friday, boosted by demand for blockbuster asthma drug Dupixent ...

Sanofi has dropped its respiratory syncytial virus (RSV) vaccine for toddlers after the candidate underperformed in a phase 3 ...

Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the ...

Sales of Sanofi’s COVID-19 and flu vaccines fell 17% in the third quarter amid declining vaccination rates and pricing ...

The French pharma’s overall vaccine sales declined 8% in the quarter, with a key driver being slower-than-usual uptake of flu ...

Sanofi SA (SNY) reports a 7% revenue increase, with significant contributions from DUPIXENT and new product launches, despite ...

Sanofi’s Q3 saw total revenues rise 7% CER, with Dupixent contributing over €4 billion for the first time. Click here to read ...

The United States Adult Vaccine Market is projected to soar to US$ 11.10 billion by 2033, up from US$ 6.55 billion in 2024, ...

Sanofi has reported that the high-dose formulation of its influenza vaccine, Elfueda (known as Fluzone High-Dose in the US), ...

The MoU supports Saudi Vision 2030 and the National Transformation Program’s focus on localizing healthcare manufacturing ...

Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose Compared to ...